Every one of those 1 sits in a single category, pharma. Aurobindo Pharma USA, Inc. is most often covered alongside Aurobindo Pharma Ltd., which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Aurobindo Pharma USA, Inc., all published on July 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Aurobindo Pharma USA, Inc.
Every one of those 1 sits in a single category, pharma. Aurobindo Pharma USA, Inc. is most often covered alongside Aurobindo Pharma Ltd., which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Aurobindo Pharma USA, Inc., all published on July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Aurobindo Pharma USA, Inc.. Shared-story counts are live from our verified record — not editorial picks.
The U.S. Federal Trade Commission approved Aurobindo Pharma USA’s $250 million acquisition of Lannett Company LLC, clearing the final regulatory hurdle.
Aurobindo Pharma’s US subsidiary receives FTC clearance for its $250 million cash-free acquisition of Lannett, adding a complex generics and controlled substances portfolio expected to be immediately accretive to EPS and generate significant synergies.